UNITED STATES PATENT AND TRA	DEMARK OFFICE
BEFORE THE PATENT TRIAL AND	APPEAL BOARD
MEDTRONIC, INC. Petitioner	
V.	
NUVASIVE, INC. Patent Owner	
Case IPR2013-00506 Patent 8,361,156	

PETITIONER'S RESPONSE TO PATENT OWNER'S MOTION FOR OBSERVATION REGARDING CROSS-EXAMINATION OF LOIC JOSSE



I. Introduction

Pursuant to the Board's Order dated October 15, 2014, Petitioner Medtronic, Inc. ("Petitioner") submits the following responses to Patent Owner NuVasive, Inc.'s ("Patent Owner") Motion for Observation Regarding Cross-Examination of Loic Josse.¹

II. Responses

A. Response to Observation #1

In Ex. 2038, at 19:25 to 20:11 and 31:15 to 32: 6, Mr. Josse testified about U.S. Patent No. 6,156,037 as follows:

Page 19

25 Q. Wonderful. In that section you

Page 20

2 actually state that the "above mentioned

3 U.S. patent number 5,727,661 issued

4 January 30, 1998 to Michaelson, the

5 disclosure of which is incorporated herein

6 by reference to an extent which may be

7 needed to understand the device and method

8 of the present invention."

9 That is written in your '037

10 patent. Correct?



¹ Patent Owner includes in the exhibit list preceding the Motion Exhibit Nos. 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, each of which have been expunged by the Order dated October 15, 2014. *See* IPR2013-00506, Paper 37, at 5 (PTAB October 15, 2014).

11 A. Correct.

Page 31

- 15 A. So, in the claim, the first
- 16 claim, this is described as implants can
- 17 have elongated length. As I describe here
- 18 in my declaration, length of implant is
- 19 dependent on the approach of the implant
- 20 as well as the anatomy of the patient,
- 21 anatomy of the vertebra where the device
- 22 or implant is going to be implanted as
- 23 described in the claim number 1 in the
- 24 disc space in the case of this Boomerang
- 25 cages.

Page 32

- 2 Yes, the cage can be
- 3 40 millimeters long or even longer if
- 4 necessary or if directed by the anatomy of
- 5 the patient or by the approach used to
- 6 implant.

This testimony is relevant to the reply at pages 3-5 regarding implant length.

B. Response to Observation #2

In Ex. 2038, at 37:19 to 38:4, Mr. Josse testified as follows:

Page 37

- 19 Q. On this page, in the left side
- 20 of the page, kind of two thirds of the way
- 21 down, it identifies standard cages.
- 22 Correct? Do you see that?
- 23 A. Correct. I see that.
- 24 Q. And it lists the length of those
- 25 standard cages as 30 millimeters,

Page 38

- 2 35 millimeters or 40 millimeters.
- 3 Correct?
- 4 A. Correct.



This testimony is relevant to Mr. Josse's testimony at ¶ 4 of the Josse Declaration where he states that "Medtronic has commercialized interbody spinal fusion implants having a length of at least 40 mm." Ex. 1116, at ¶ 4.

C. Response to Observation #3

In Ex. 2038, at 48:19 to 49:12, Mr. Josse testified as follows:

Page 48

19 O. And this is a draft of the

20 marketing materials. Correct?

21 [objection omitted]

22 [objection omitted]

23 A. No. Actually, I believe this is

24 the final version as we describe at the

25 last page where you can find the Medtronic

Page 49

2 reference and date of release.

3 Q. But the cover page says "draft

4 copy." Correct?

5 A. Correct. But I believe it is a

6 typo. I don't know for which reason they

7 mention "draft copy, internal use only."

8 Q. I didn't understand your last

9 response. Can you say it again, please?

10 A. I said I don't know why the

11 mention "Draft copy, for internal use

12 only" remained on the final version.

This testimony is relevant to Ex. 2038, at 43:6-22, because it places that testimony in the proper context, and to Mr. Josse's testimony at ¶ 4 of the Josse Declaration where he indicates that the Appendix D to his declaration was publicly available.



D. Response to Observation #4

In Ex. 2038, at 45:22 to 46:10, Mr. Josse testified as follows:

Page 45

22 Q. In paragraph 4 you state that

23 you are aware of Medtronic commercializing

24 interbody fusion implants having a length

25 of at least 40 millimeters. Correct?

Page 46

2 A. That is correct, in Europe.

3 Yes, that is correct.

4 Q. The only implant you identify in

5 paragraph 4 being commercialized is the

6 Butterfly implant. Correct?

7 MR. SCHWARTZ: Objection to

8 form.

9 A. That is correct, with the

10 Boomerang implant mentioned before.

This testimony is relevant to Mr. Josse's testimony at ¶ 4 of the Josse Declaration where he indicates that the Butterfly implant described in Appendix D to his declaration was commercialized.

E. Response to Observation #5

In Ex. 2038, at 71:19 to 76:3, Mr. Josse testifies about Appendix B to his declaration. *See* Ex. 2038, at 71:19-22 ("Now, if you turn back to Appendix B, which is the email exchange between Ming Liu and gfrey2sun@aol.com? Yes."). This is relevant to Ex. 2038, at 73:2-17, because it shows that Mr. Josse was testifying to the dimension D as being the width of the implant described in



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

